UFPT · UFP Technologies, Inc. · Stock research

Current Thesis

UFP Technologies designs and manufactures single-use components and packaging for medtech OEMs. The leg on offer is an acceleration story: Q2 2026, released 2026-08-03, put organic growth at 12.4% against 6.8% for the first six months, with adjusted EPS of $2.92 versus a $2.50 consensus and sales of $173.964M versus $159.383M expected. Price responded — the 2026-08-14 close of $321.76 sits 3.9% under the 52-week high of $334.84 after a 50.4% three-month advance. The narrative is ACCELERATING, dated by the 2026-08-03 beat and the stock's 2026-08-04 appearance in the day's upside movers list. What it is not is early: RSI(14) at 76.7, the Executive Chairman selling ~$5.0M into the print, and no scheduled company event for roughly eleven weeks.

Bullish and bearish views on UFP Technologies, Inc.

The model's bull view on UFP Technologies, Inc. (UFPT), in brief: Q2 2026 net sales $174.0M, +15.1% versus $151.2M in Q2 2025; organic sales growth 12.4% (press release, 2026-08-03). The bear view: The company declined to give guidance for the remainder of 2026. Both cases follow in full.

Bull Case

• Q2 2026 net sales $174.0M, +15.1% versus $151.2M in Q2 2025; organic sales growth 12.4% (press release, 2026-08-03). The organic line accelerated against the 6.8% recorded for the six months ended 2026-06-30.
• Adjusted EPS $2.92 against a $2.50 consensus; GAAP EPS $2.68. Net income $20.9M, +21.4% YoY — earnings compounding faster than the top line.
• Gross margin 29.3% versus 28.8% in Q2 2025; first-half gross margin 29.0% versus 28.6%. Adjusted EBITDA $36.4M, +14.3% YoY.
• Growth is broadening inside MedTech: top five customers grew 14.7% in the quarter while the balance of the MedTech business grew 19.7% (2026-08-03 release). The non-concentrated portion is the faster line.
• On the Q2 call (2026-08-04), CEO Mitchell Rock pointed to an eight-figure 2027 revenue contribution from robotics programs and said the acquisition pipeline is unchanged with 5–10 opportunities under evaluation (Seeking Alpha summary of the call).
• The 2026-08-03 release cites continued investment in Dominican Republic operations to expand capacity and improve cost structure — the margin expansion has a stated mechanism behind it.

Bear Case

• The company declined to give guidance for the remainder of 2026. Between now and the Q3 print there is no scheduled information flow, so the stock trades on multiple alone.
• Executive Chairman R. Jeffrey Bailly sold 15,695 shares on 2026-08-06 and 2026-08-07 for approximately $4.997M at prices ranging $315.06–$320.82, disclosed on a Form 4 filed 2026-08-10 and preceded by a Form 144 on 2026-08-06. That is distribution at the highest prices the shares have printed.
• The gap between the 12.4% Q2 organic rate and the 6.8% first-half rate implies a materially slower Q1 — an inference from the two disclosed figures, not a company statement. One quarter of 12.4% is a datapoint, not an established trend.
• Price has run 50.4% in three months against a 15.1% revenue growth rate. Multiple expansion, not delivery, has done most of the work in that window.
• Sell-side targets sit close to the tape rather than above it: one aggregator shows a 10-analyst average target of $330.99 against the 2026-08-14 close of $321.76, with Lake Street's published target of $344 (raised from $300) the high-side marker. The undated Lake Street headline is the only firm-level revision located.
• Top-five customer concentration is disclosed as its own growth line, which is itself an acknowledgement that a small number of OEM programs drive the base.

Setup & Price Structure

• Reference close 2026-08-14: $321.76. 52-week high $334.84, so the stock is 3.9% below it. Three-month return +50.4%.
• RSI(14) 76.7 — extended, and consistent with a post-earnings breakout rather than a base.
• The 2026-08-06/07 insider sales cleared between $315.06 and $320.82, a band immediately beneath the reference close. It marks a price zone where a large, informed holder was willing to transact size.
• Life-cycle: ACCELERATING. Dating it: the 2026-08-03 beat, the record quarterly sales/net income/EPS language in the same release, the 2026-08-04 movers coverage, and price within 3.9% of the high.
• Crowding observables, stated as observables: RSI above 76; ~$5.0M of Executive Chairman selling inside four sessions of the print; a Form 144 filed 2026-08-06; no confirmed company catalyst inside 30 days; consensus target roughly at the current quote.
• The structurally cleaner entry is a pullback that holds the $300 area and builds a shelf above it, not a chase into the high. Nothing in the tape has yet produced that base.

Catalyst Calendar (next 30 days)

• 2026-08-15 → 2026-09-14: no confirmed company event. No earnings, no scheduled investor day, no dated regulatory item located. The window is empty by design — the company does not guide between prints.
• ~2026-11-04 (est.) — the roughly 90-day window contemplated by the 2026-08-06 Form 144 runs out. Further Form 4 filings from the Executive Chairman can land at any point inside it.
• ~2026-11-02 (est.) — Q3 2026 results. Q2 was released 2026-08-03; the Q3 date is an estimate off that cadence, not a confirmed announcement.

Elapsed catalysts

• Undated — an acquisition. The Q2 call (2026-08-04) described 5–10 opportunities under evaluation; any deal would be an unscheduled headline, and a debt- or equity-funded one changes the capital structure the current multiple assumes. (passed 11d ago)

What Would Change Our Mind

The leg rests on the 12.4% Q2 organic rate being the new run-rate rather than a single strong quarter against an easy comparison. Three things would break it.

First, the structure: a weekly close below $300 gives up the entire post-Q2 momentum shelf and takes price beneath the $315.06–$320.82 zone where the Executive Chairman transacted on 2026-08-06/07. That is the gradeable level.

Second, the fundamental: Q3 2026 organic growth printing back below the 6.8% first-half rate would say the acceleration was a comparison artifact. Because the company gives no guidance, nothing tests this before the print.

Third, decay: if September and October pass with no acquisition, no new program announcement and price capped under the 52-week high of $334.84 while RSI unwinds, the narrative has moved from ACCELERATING to MATURING and the bid thins on its own. Continued officer or director selling inside the Form 144 window would reinforce that reading.

Correlation Notes

• The name tracks medtech procedure volumes and OEM outsourcing demand rather than the broad AI complex; comparables for read-across are contract manufacturers and component suppliers into medical devices, Integer Holdings among them.
• Customer-side risk is idiosyncratic: a top-five OEM cutting or reshoring a program shows up in UFPT's numbers with a lag, not in sector indices.
• Manufacturing exposure to Dominican Republic operations puts US trade and tariff policy on imported medical components in the correlation set. The 2026-08-03 release contained no tariff commentary — an absence, not a clearance.
• As a mid-cap with a 50.4% three-month move, the shares now carry momentum-factor exposure; a factor unwind can move price independently of anything the company reports.